The Postpartum Depression market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Postpartum Depression: An Overview
Postpartum depression (PPD) is the most common non-psychotic, complication of childbearing affecting approximately 10-15% of women and as such, represents a considerable public health problem affecting women and their families. The postnatal period is well established as an increased time of risk for the development of serious mood disorders. There are three common forms of postpartum affective illness: the blues (baby blues, maternity blues), postpartum (or postnatal) depression, and puerperal (postpartum or postnatal) psychosis each of which differs in its prevalence, clinical presentation, and management.
Postpartum depression usually begins within 1–12 months after delivery. In some women, post-partum blues simply continue and become more severe. In others, a period of wellbeing after delivery is followed by a gradual onset of depression. The patterns of symptoms in women with postpartum depression are similar to those in women who have depression unrelated to childbirth.
The aspect of the types of PPD cited by Postpartum Depression.org, it was found that Postpartum Obsessive-Compulsive Disorder (OCD), Postpartum Panic Disorder, and Postpartum Post-Traumatic Stress Disorder can be seen in 3–5%, up to 10%, and over 9% of postpartum women, respectively.
Postpartum Depression Market Key Facts
According to the Centers for Disease Control and Prevention (CDC), depression is a common and serious disorder. A study by CDC showed that about 1 out of 10 women in the United States experience symptoms of depression. Also, by using the Pregnancy Risk Assessment Monitoring System (PRAMS), CDC research showed that nationally, about 1 in 9 women experience symptoms of postpartum depression.
The total diagnosed prevalent population of Postpartum Depression in the seven major markets was found to be 1,134,800 in 2017.
In Japan, the diagnosed prevalence of Postpartum Depression cases was found to be 116,280 in 2017.
In the EU5 countries, the diagnosed prevalence of Postpartum Depression was found to be maximum in France with 98,040 cases, followed by the United Kingdom with 97,750 cases in 2017. While, the least number of cases were found in Spain, i.e., 56,375 in 2017.
According to the American College of Obstetricians and Gynecologists, It is estimated that 14–23% of pregnant women experience depression during pregnancy, and 5–25% experience depression Postpartum.
The Postpartum Depression market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Postpartum Depression market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Postpartum Depression market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Postpartum Depression Epidemiology
The epidemiology section covers insights about the historical and current Postpartum Depression patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Postpartum Depression Epidemiology Segmentation
Total Diagnosed Prevalent Population of Postpartum Depression
Type-specific Diagnosed Prevalence of Postpartum Depression
Postpartum Depression Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postpartum Depression market or expected to get launched in the market during the study period. The analysis covers Postpartum Depression market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Postpartum Depression Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/postpartum-depression-market
Postpartum Depression Therapeutics Analysis
The dynamics of the Postpartum Depression (PPD) market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise efficient treatment options. The launch of emerging therapies is expected during the forecast period.
Postpartum Depression Companies:
And many others.
Postpartum Depression Therapies Covered in the Report include:
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/postpartum-depression-market
Table of Content
1. Key Insights
2. Executive Summary
3. Postpartum Depression Competitive Intelligence Analysis
4. Postpartum Depression Market Overview at a Glance
5. Postpartum Depression Disease Background and Overview
6. Postpartum Depression Patient Journey
7. Postpartum Depression Epidemiology and Patient Population
8. Postpartum Depression Treatment Algorithm, Current Treatment, and Medical Practices
9. Postpartum Depression Unmet Needs
10. Key Endpoints of Postpartum Depression Treatment
11. Postpartum Depression Marketed Products
12. Postpartum Depression Emerging Therapies
13. Postpartum Depression Seven Major Market Analysis
14. Attribute Analysis
15. Postpartum Depression Market Outlook (7 major markets)
16. Postpartum Depression Access and Reimbursement Overview
17. KOL Views on the Postpartum Depression Market.
18. Postpartum Depression Market Drivers
19. Postpartum Depression Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/postpartum-depression-market
More Trending Healthcare Reports By DelveInsight
DelveInsight’s “Epstein Barr virus (EBV) Market” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Epstein Barr virus (EBV) market trends in 7MM. As per DelveInsight, the Epstein Barr virus (EBV) Market is expected to grow in the coming years owing to the active participation of key companies such as Atara Biotherapeutics, AlloVir, Tessa Therapeutics, Viracta Therapeutics, Seagen, RAPT Therapeutics, Merck, Eutilex, Atara Biotherapeutics, Labolife, and Others.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States